Cumberland Pharmaceuticals Inc. CPIX
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.62% | 4.92% | -8.73% | -96.13% | -98.04% |
| Total Other Revenue | -- | 210.12% | -- | -- | -- |
| Total Revenue | -1.62% | 31.08% | -8.73% | -96.13% | -98.04% |
| Cost of Revenue | -- | 13.40% | -25.26% | -- | -- |
| Gross Profit | -1.62% | 35.21% | -5.92% | -95.32% | -97.59% |
| SG&A Expenses | 5.67% | 35.72% | -0.95% | -62.07% | -66.29% |
| Depreciation & Amortization | 14.75% | -30.57% | -6.37% | -99.47% | -99.45% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.15% | 22.58% | -4.85% | -67.81% | -72.13% |
| Operating Income | -7.69% | 25.56% | -15.99% | -203.84% | -45.67% |
| Income Before Tax | -9.71% | 28.24% | -27.39% | -174.24% | -37.58% |
| Income Tax Expenses | -31.58% | 140.70% | -50.00% | -50.00% | -50.00% |
| Earnings from Continuing Operations | -9.63% | 24.87% | -26.81% | -171.92% | -37.05% |
| Earnings from Discontinued Operations | -111.12% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -129.21% | 872.73% | 216.90% | -132.35% | 120.32% |
| Net Income | -361.68% | 25.85% | -25.69% | 31.77% | 164.59% |
| EBIT | -7.69% | 25.56% | -15.99% | -203.84% | -45.67% |
| EBITDA | 2.09% | 4.72% | -60.36% | -1,948.94% | -135.37% |
| EPS Basic | -361.47% | 30.74% | -18.02% | 35.63% | 160.90% |
| Normalized Basic EPS | -10.35% | 34.40% | -2.15% | -- | -24.51% |
| EPS Diluted | -361.47% | 32.67% | -18.18% | 38.13% | 160.07% |
| Normalized Diluted EPS | -10.35% | 34.40% | -2.15% | -- | -24.51% |
| Average Basic Shares Outstanding | 0.12% | 7.05% | 6.44% | 5.97% | 5.99% |
| Average Diluted Shares Outstanding | 0.12% | 7.05% | 6.44% | 5.97% | 5.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |